The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The impact of comorbidity on costs and effects of second-line treatment among elderly metastatic colon cancer patients.
Andinet Woldemichael
No relevant relationships to disclose
Ebere Onukwugha
Consultant or Advisory Role - Janssen
Honoraria - ICU Medical
Research Funding - Amgen; Bayer
Zhiyuan Zheng
No relevant relationships to disclose
Nader Hanna
No relevant relationships to disclose
Brian S. Seal
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
C. Daniel Mullins
Consultant or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Novartis; Novo Nordisk; Pfizer
Honoraria - Celgene
Research Funding - Bayer; Pfizer